Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma

Bookmark and Share
Published: 3 Jul 2020
Views: 654
Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA

Dr Elias Jabbour speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

He outlines the rationale behind this phase I dose-escalation study, which assessed the safety and efficacy of venetoclax plus navitoclax and chemotherapy, for the treatment of relapsed/refractory (R/R) acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LL) in adult and paediatric patients.

Dr Jabbour details the methods and results of the study, which found that this combination is well-tolerated and shows promising clinical efficacy in heavily pretreated patients.